218 related articles for article (PubMed ID: 24558096)
1. A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.
Voisset C; Daskalogianni C; Contesse MA; Mazars A; Arbach H; Le Cann M; Soubigou F; Apcher S; Fåhraeus R; Blondel M
Dis Model Mech; 2014 Apr; 7(4):435-44. PubMed ID: 24558096
[TBL] [Abstract][Full Text] [Related]
2. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation.
Apcher S; Daskalogianni C; Manoury B; Fåhraeus R
PLoS Pathog; 2010 Oct; 6(10):e1001151. PubMed ID: 20976201
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
4. Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA.
Reznichenko O; Quillévéré A; Martins RP; Loaëc N; Kang H; Lista MJ; Beauvineau C; González-García J; Guillot R; Voisset C; Daskalogianni C; Fåhraeus R; Teulade-Fichou MP; Blondel M; Granzhan A
Eur J Med Chem; 2019 Sep; 178():13-29. PubMed ID: 31173968
[TBL] [Abstract][Full Text] [Related]
5. A yeast model for the mechanism of the Epstein-Barr virus immune evasion identifies a new therapeutic target to interfere with the virus stealthiness.
Lista MJ; Martins RP; Angrand G; Quillévéré A; Daskalogianni C; Voisset C; Teulade-Fichou MP; Fåhraeus R; Blondel M
Microb Cell; 2017 Aug; 4(9):305-307. PubMed ID: 28913345
[TBL] [Abstract][Full Text] [Related]
6. Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA.
Lista MJ; Martins RP; Billant O; Contesse MA; Findakly S; Pochard P; Daskalogianni C; Beauvineau C; Guetta C; Jamin C; Teulade-Fichou MP; Fåhraeus R; Voisset C; Blondel M
Nat Commun; 2017 Jul; 8():16043. PubMed ID: 28685753
[TBL] [Abstract][Full Text] [Related]
7. Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBV-encoded antigen, EBNA1.
Tellam JT; Lekieffre L; Zhong J; Lynn DJ; Khanna R
PLoS Pathog; 2012 Dec; 8(12):e1003112. PubMed ID: 23300450
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells.
Mautner J; Pich D; Nimmerjahn F; Milosevic S; Adhikary D; Christoph H; Witter K; Bornkamm GW; Hammerschmidt W; Behrends U
Eur J Immunol; 2004 Sep; 34(9):2500-9. PubMed ID: 15307182
[TBL] [Abstract][Full Text] [Related]
9. Type I arginine methyltransferases are intervention points to unveil the oncogenic Epstein-Barr virus to the immune system.
Angrand G; Quillévéré A; Loaëc N; Dinh VT; Le Sénéchal R; Chennoufi R; Duchambon P; Keruzoré M; Martins RP; Teulade-Fichou MP; Fåhraeus R; Blondel M
Nucleic Acids Res; 2022 Nov; 50(20):11799-11819. PubMed ID: 36350639
[TBL] [Abstract][Full Text] [Related]
10. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
Yin Y; Manoury B; Fåhraeus R
Science; 2003 Sep; 301(5638):1371-4. PubMed ID: 12958359
[TBL] [Abstract][Full Text] [Related]
11. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.
Blake NW; Moghaddam A; Rao P; Kaur A; Glickman R; Cho YG; Marchini A; Haigh T; Johnson RP; Rickinson AB; Wang F
J Virol; 1999 Sep; 73(9):7381-9. PubMed ID: 10438828
[TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome.
Lee EK; Kim SY; Noh KW; Joo EH; Zhao B; Kieff E; Kang MS
Antiviral Res; 2014 Apr; 104():73-83. PubMed ID: 24486954
[TBL] [Abstract][Full Text] [Related]
14. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
[TBL] [Abstract][Full Text] [Related]
15. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
Quinn LL; Williams LR; White C; Forrest C; Zuo J; Rowe M
J Virol; 2016 Jan; 90(1):356-67. PubMed ID: 26468525
[TBL] [Abstract][Full Text] [Related]
16. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers.
Jiang L; Xie C; Lung HL; Lo KW; Law GL; Mak NK; Wong KL
Theranostics; 2018; 8(19):5307-5319. PubMed ID: 30555548
[TBL] [Abstract][Full Text] [Related]
17. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
Tellam J; Connolly G; Green KJ; Miles JJ; Moss DJ; Burrows SR; Khanna R
J Exp Med; 2004 May; 199(10):1421-31. PubMed ID: 15148340
[TBL] [Abstract][Full Text] [Related]
18. GAP31 from an ancient medicinal plant exhibits anti-viral activity through targeting to Epstein-Barr virus nuclear antigen 1.
Shen CL; Huang WH; Hsu HJ; Yang JH; Peng CW
Antiviral Res; 2019 Apr; 164():123-130. PubMed ID: 30817940
[TBL] [Abstract][Full Text] [Related]
19. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
[TBL] [Abstract][Full Text] [Related]
20. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.
Blake N; Lee S; Redchenko I; Thomas W; Steven N; Leese A; Steigerwald-Mullen P; Kurilla MG; Frappier L; Rickinson A
Immunity; 1997 Dec; 7(6):791-802. PubMed ID: 9430224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
